Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Titel:
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Auteur:
Goldman, Jonathan W Dvorkin, Mikhail Chen, Yuanbin Reinmuth, Niels Hotta, Katsuyuki Trukhin, Dmytro Statsenko, Galina Hochmair, Maximilian J Özgüroğlu, Mustafa Ji, Jun Ho Garassino, Marina Chiara Voitko, Oleksandr Poltoratskiy, Artem Ponce, Santiago Verderame, Francesco Havel, Libor Bondarenko, Igor Każarnowicz, Andrzej Losonczy, György Conev, Nikolay V Armstrong, Jon Byrne, Natalie Thiyagarajah, Piruntha Jiang, Haiyi Paz-Ares, Luis